Loading
In women with metastatic HER2-negative breast cancer and an inherited BRCA mutation, the PARP inhibitor tablet olaparib delayed progression by almost three months compared with chemotherapy and caused fewer severe side effects.
Phase 3 trial of 302 patients with HER2-negative metastatic breast cancer and a germline BRCA1 or BRCA2 mutation, previously treated with up to two chemotherapy lines, randomised 2:1 to olaparib or single-agent chemotherapy of physician's choice.
Median progression-free survival was 7.0 versus 4.2 months (hazard ratio 0.58) with a response rate of 59.9 versus 28.8 percent; overall survival was not significantly different, though a benefit appeared in patients who had not received chemotherapy for metastatic disease.
Germline BRCA testing became part of metastatic breast cancer work-up, and olaparib (with talazoparib after EMBRACA) is a standard option, especially for triple-negative disease.
Shares Mark E. Robson, OlympiAD, Olaparib, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, New England Journal of Medicine.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, New England Journal of Medicine.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, New England Journal of Medicine.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Metastatic triple-negative breast cancer, New England Journal of Medicine.